The FDA has completed its 30-day review of an application for Hepzato in combination with standard of care in liver-dominant ...

Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic ...

SIRT with 90Y resin microspheres led to durable disease control in patients with gastrointestinal stromal tumor liver ...

Cancer spreads fast and hits hard, especially when it reaches other organs. Once that happens, treatments become less ...

Symptoms, and Treatment Liver cancer is one of the most challenging forms of cancer, often developing quietly before showing any clear signs. It begins when abnormal cells form in the liver, a vital ...

Delcath Systems, Inc. announced that it has received clearance from the FDA to initiate patient enrollment of a phase 2 clinical ...

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer Delcath Systems, Inc. (NASDAQ: DCTH), an ...

Elevated circulating tumor DNA fraction and tumor suppressor gene loss are associated with worse prognosis in patients with prostate cancer liver metastases. Elevated circulating tumor DNA (ctDNA ...

It can take years for prostate cancer to turn castration-resistant, when cancer cells stop responding to hormonal therapy.

A humanized antibody undermines the metabolic checkpoint mediated by CD36 to restore anti-tumor immunity in mouse models of ...